Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 272-338-9 | CAS number: 68814-67-5 A complex combination obtained from various petroleum refining operations. It consists of hydrogen and hydrocarbons having carbon numbers predominantly in the range of C1 through C3.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Remarks:
- combined repeated dose and reproduction / developmental screening
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant (except for minor exception listed below), guideline study, available as unpublished report, no restrictions, fully adequate for assessment.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 010
- Report date:
- 2010
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- yes
- Remarks:
- no lot number available of test material
- Qualifier:
- according to guideline
- Guideline:
- other: EPA OPPTS 870.3650
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Ethane
- EC Number:
- 200-814-8
- EC Name:
- Ethane
- Cas Number:
- 74-84-0
- IUPAC Name:
- ethane
- Details on test material:
- - Name of test material (as cited in study report): ethane
- Supplier: MG Industries, 3 Great Valley Parkway, Malvern, Pennsylvania 19355, USA
- Substance type: Industrial gas
- Physical state: colourless gas
- Analytical purity: 99.0% per supplier
- Lot/batch No.: Not available
- Stability under test conditions: 99.86% before study, 99.88% after study
- Storage condition of test material: Ambient
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Species: Albino rats (Outbred) VAF/Plus®, Sprague-Dawley derived (CD®), Crl:CD®(SD)IGS BR
- Source: Charles River Laboratories, Raleigh, North Carolina 27610, USA
- Age at study initiation: Approximately 8 weeks
- Weight at study initiation: Males mean 256 g (range 230-284 G); females mean 197 g (range 167-217 g)
- Fasting period before study: None
- Housing: Individually in stainless steel suspended cages with wire mesh floors and fronts (except for mating period when 1 male and 1 female were housed together)
- Diet: Certified Rodent diet No 5002 (PMI Nutrition International, St Louis, Missouri, USA) ad libitum
- Water: Municipal water ad libitum
- Acclimation period: Approximately 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature: 20.7 - 23.2°C
- Humidity: 19.96-74.37%
- Air changes (per hr): Not reported
- Photoperiod: 12 hrs dark / 12 hrs light
IN-LIFE DATES: From: 24 November 2003 To: 17 January 2004
Administration / exposure
- Route of administration:
- inhalation: gas
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: air
- Remarks on MMAD:
- MMAD / GSD: MMAD: 1.607, 1.477, 1.643, 1.428 µm; GSD: 2.045, 2.385, 2.005, 1.897; total mass concentration: 3.04 x 10E-3, 3.24 x10E-3, 3.61xE10-3, 2.69x10E-3 mg/m3 for target exposure concentrations of 0, 1600, 5000 and 16000 ppm respectively.
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: 1000 L glass and stainless steel whole-body exposure chamber
- Method of holding animals in test chamber: housed individually, the placement of animals in the chamber was rotated daily to ensure uniform exposure
- System of generating particulates/aerosols: the test substance was delivered from a single cylinder, through a regulator and two backpressure gauges via a flowmeter into the exposure chambers
- Time to T99: 23 minutes maximum
- Airflow rate: 204 Lpm
- Temperature and humidity in chamber: 20-24°C, 28-59%
- Oxygen level: at least 19%
- Air flow rate: minimum flow rate of 200 L/minute
- Air change rate: final airflow set to provide at least one air change in 5 mins (12 air changes/hour)
- Method of particle size determination: determined weekly using a TSI Aerodynamic Particle Sizer
- Treatment of exhaust air: filtered through a system which consisted of a coarse filter, a HEPA filter and an activated charcoal bed
TEST ATMOSPHERE
- Brief description of analytical method used: Infrared spectrophotometer (IR) 4 times per chamber per day
- Samples taken from breathing zone: yes - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Exposure levels were determined using an infrared spectrophotometer 4 times/chamber/day. The test substance was evenly distributed within each chamber. The mean (± SD) analytical concentrations were 0.0 ± 0.0, 1599 ± 59, 5186 ± 285 and 16380 ± 626 ppm.
- Duration of treatment / exposure:
- Males: 2 weeks prior to mating and a minimum of 28 days after mating.
Females: 2 weeks prior to mating and post-mating for an additional 4 weeks. - Frequency of treatment:
- 6 hours/day, 7 days/week
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0, 1600, 5000 and 16000 ppm
Basis:
other: target concentration
- Remarks:
- Doses / Concentrations:
0.0 ± 0.0, 1599 ± 59, 5186 ± 285 and 16380 ± 626 ppm
Basis:
analytical conc.
- No. of animals per sex per dose:
- 12/sex/group
- Control animals:
- yes, sham-exposed
- Details on study design:
- - Dose selection rationale: Based on results of a 2-week range-finding study (HLS Study No. 03-6144) which showed no toxicity at 160, 1600 and 16000 ppm). The high level was established at 16000 ppm since it is 50% of the lower explosion limit for the test substance.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily (mortality and clinical condition)
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Weekly
BODY WEIGHT: Yes
- Time schedule for examinations: At randomisation, first day of exposure and weekly thereafter.
FOOD CONSUMPTION: Yes
- Time schedule for examinations: Pre-test and weekly thereafter.
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Study termination
- Anaesthetic used for blood collection: Yes (CO2/O2)
- Animals fasted: Yes (overnight)
- How many animals: 12/sex/group
- Parameters examined: haemoglobin concentration, haematocrit, erythrocyte count, platelet count, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, total leukocyte count, reticulocyte count, differential leukocyte count, erythrocyte and platelet morphology (from peripheral blood smear), prothrombin time, activated partial thromboplastin time..
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Study termination
- Anaesthetic used for blood collection: Yes (CO2/O2)
- Animals fasted: Yes (overnight)
- How many animals: 12/sex/group
- Parameters examined: aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, blood urea nitrogen, creatinine, glucose, cholesterol, total protein, triglycerides, albumin, total bilirubin, sodium, potassium, chloride, calcium, inorganic phosphorus, gamma-glutamyl transpeptidase, globulin, albumin/globulin ratio
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: During last week of exposure
- Dose groups that were examined: All
- Battery of functions tested: sensory observations (startle response to auditory stimuli, tail pinch response), neuromuscular observations (grip strength - hindlimb and forelimb), physical observations (rectal temperature) and motor activity assessments - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (all animals)
- examined: external surfaces, all orifices, cranial cavity, nasal cavity, neck and its associated tissues and organs, thoracic, abdominal and pelvic cavities and their associated tissues and organs and external surfaces of the brain.
ORGAN WEIGHTS: Yes (all animals)
- organs weighed: adrenal glands, brain, epididymes, heart, kidneys, liver, lungs (with mainstem bronchi), ovaries (with oviducts), spleen, testes, thymus, uterus with vagina.
HISTOPATHOLOGY: Yes (control and high dose only).
- tissues examined: adrenal glands, bone (sternum/femur), brain (cerebellum, cerebrum and cerebellum), epididymes, heart, kidneys, large intestine (caecum, colon and rectum), liver, lungs (with mainstream bronchi), lymph node (mesenteric), lymph node (mediastinal), mammary glands (with adjacent skin), ovaries (with oviducts), prostate, seminal vesicles, small intestine (duodenum, ileum and jejunum), spinal cord (cervical, thoracic and lumbar), spleen, stomach, testes, thymus, thyroids with parathyroids, tibial nerve, trachea, urinary bladder, uterus with vagina, all macroscopic lesions and tissue masses. - Statistics:
- Group mean values of parameters for all the exposure groups were compared to the control group mean values at each time interval, using appropriate statistical methods.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Details on results:
- No systemic toxicity (no effects on survival, haematological or clinical chemistry parameters, food consumption, body weight, organ weight, and histopathology) or neurological effects (as measured by clinical observations, functional observational battery, and motor activity) were observed.
Marginally lower food consumption at 16000 ppm compared to controls was seen during 1st week of exposure, but differences from control were less than 5% and were transient and, therefore, were considered not to be adverse.
Effect levels
open allclose all
- Dose descriptor:
- NOAEC
- Remarks:
- systemic toxicity
- Effect level:
- 16 000 ppm
- Sex:
- male/female
- Basis for effect level:
- other: highest concentration tested
- Dose descriptor:
- NOAEC
- Remarks:
- systemic toxicity
- Effect level:
- 19 678 mg/m³ air
- Sex:
- male/female
- Basis for effect level:
- other: highest concentration tested
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
No systemic toxicity (no effects on survival, haematological or clinical chemistry parameters, food consumption, body weight, organ weight, and histopathology) or neurological effects (as measured by clinical observations, functional observational battery, and motor activity) were observed.
Applicant's summary and conclusion
- Conclusions:
- No systemic toxicity (no effects on survival, haematological or clinical chemistry parameters, feed consumption, body weight, organ weight, and histopathology) or neurological effects (as measured by clinical observations, functional observational battery, and motor activity) were observed.
The no observed adverse effect concentration (NOAEC) of ethane was 16000 ppm in this study. Equivalent to 19678 mg/m3 - Executive summary:
The study assessed the potential toxicity, including neurotoxicity and reproductive performance in male and female rats following ethane exposure at 1600, 5000and 16000 ppm (highest exposure level was 50% of the lower explosive limit). It also was designed to investigate effects in both sexes on mating behaviour and on gonadal function, as well as effects on conception, development, parturition and pup survival to lactation day 4.
Male and female rats were exposed for 6 hours/day, 7 days/week for 2 weeks prior to mating initiation. Main study males and females were then evaluated for subchronic effects and were exposed once daily (6 hours/day), seven days/week for 4 weeks (28 days).
There was no effect on survival. There were no exposure-related clinical effects or effects on body weight, food consumption, FOB or motor activity parameters for either sex (except the16000 ppm exposed animals showed marginally lower food consumption during the first week of exposures).There were no exposure-related differences in haematology, clinical chemistry and no macroscopic or microscopic changes at post-mortem.
Exposure of male and female rats to target concentrations of 1600, 5000 or 16000 ppm of ethane by whole-body inhalation for 4-6 weeks resulted in no general systemic or neurotoxic effects apart from a very marginal reduction of food consumption during the first week of exposure at 16000 ppm and this transient difference was not considered adverse.
A no-observed-adverse effect concentration (NOAEC) of 16000 ppm was determined for all endpoints. Equivalent to 19678 mg/m3 (mw 30.07g/mol).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.